评估子宫内膜异位症患者尿液烯醇化酶 I 水平升高。
Evaluation of elevated urinary enolase I levels in patients with endometriosis.
机构信息
Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine , Seoul , Republic of Korea .
出版信息
Biomarkers. 2014 Feb;19(1):16-21. doi: 10.3109/1354750X.2013.863973. Epub 2013 Nov 28.
OBJECTIVE
The aim of this study is to validate and investigate the clinical value of urinary enolase I in patients with endometriosis.
METHODS
Urine samples of 39 patients with histologically confirmed endometriosis and 20 patients without endometriosis were collected. Western blot analysis and enzyme-linked immunosorbent assay were used to detect the increase of enolase I in patients' urine.
RESULTS
Urinary enolase I expression corrected for creatinine ratio (non neuronal enolase (NNE)-Cr) was significantly greater in patients with endometriosis (p = 0.026). When the diagnostic performance of NNE-Cr was evaluated with serum CA-125 combination, the area under the curve was 0.821 (95% confidence interval 0.713-0.928) with sensitivity and specificity of 76.9% and 85.0%, respectively.
CONCLUSION
Elevated urinary enolase I, in conjunction with serum CA-125, may be used as a potential biomarker for endometriosis.
目的
本研究旨在验证并探讨尿烯醇化酶 I 在子宫内膜异位症患者中的临床价值。
方法
收集 39 例经组织学证实的子宫内膜异位症患者和 20 例无子宫内膜异位症患者的尿液样本。采用 Western blot 分析和酶联免疫吸附试验检测患者尿液中烯醇化酶 I 的增加。
结果
子宫内膜异位症患者尿烯醇化酶 I 表达经肌酐校正的比值（非神经元烯醇化酶（NNE）-Cr）显著升高（p=0.026）。当结合血清 CA-125 评估 NNE-Cr 的诊断性能时，曲线下面积为 0.821（95%置信区间 0.713-0.928），灵敏度和特异性分别为 76.9%和 85.0%。
结论
尿烯醇化酶 I 升高，结合血清 CA-125，可作为子宫内膜异位症的潜在生物标志物。
Zotero 插件